Product description
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is a fragment of a larger protective protein (Body Protection Compound, BPC) with a molecular weight of approximately 40,000 Da, which was originally discovered and isolated from human gastric juice.
This peptide is distinguished by extraordinary stability - it remains intact in human gastric juice for over 24 hours, which is a unique feature among bioactive peptides. Most standard growth factors (TGF-β, EGF) are rapidly degraded in the gastric environment, limiting their potential oral applications.
BPC-157 has no sequence homology to other known peptides, which makes it a unique compound in the context of research on tissue regeneration and cytoprotection.
Mechanism of action
The mechanism of action of BPC-157 is multidirectional and includes interactions with numerous molecular pathways:
Modulation of the nitric oxide (NO) system – BPC-157 interacts with the NO system in a complex way: it induces the release of nitric oxide by activating the Src-caveolin-1-eNOS pathway, while modulating both inhibition (via L-NAME) and excessive stimulation (via L-arginine) nitric oxide synthase. This bidirectional regulation allows for the restoration of vascular homeostasis.
Activation of the VEGFR2-Akt-eNOS pathway – The peptide activates the vascular endothelial growth factor receptor type 2 (VEGFR2), which leads to the stimulation of angiogenesis without the need for other ligands or shear stress.
Effect on growth hormone receptor – Studies on rat tendon fibroblasts have shown that BPC-157 increases the expression of growth hormone receptor (GHR), which may contribute to regenerative effects in connective tissues.
Interaction with the gut-brain axis – As a gastric-derived peptide, BPC-157 fits into the concept of the gut-brain axis, where peptides native to the gastrointestinal tract can exert both peripheral and central effects. The peptide affects the serotonergic and dopaminergic systems in specific areas of the brain.
Cytoprotective effect – BPC-157 functions as a stabilizer of cell membranes (counteracting leaky gut syndrome) and a free radical scavenger, protecting cells against oxidative stress.
Directions of scientific research
BPC-157 is the subject of intensive preclinical research, mainly in animal models. A 2025 systematic review identified 36 studies published between 1993 and 2024, of which 35 were preclinical studies.
Research on tendon healing
One of the most intensively researched areas is the effect of BPC-157 on tendon regeneration. In models of severed Achilles tendon in rats, BPC-157 accelerated the growth of tendon explants, increased the migration of tendon fibroblasts, and improved cell survival under conditions of oxidative stress (H₂O₂). Biomechanical tests showed increased tensile strength, Young's modulus and improved functional gait indicators.
Muscle regeneration research
In muscle injury models (quadriceps transection, gastrocnemius injury), BPC-157 stimulated early collagen organization, egr-1 gene expression and nab2 repressor, leading to accelerated healing. The peptide also showed the ability to restore blood flow in ischemic muscles by stimulating angiogenesis.
Ligament and bone research
Preclinical studies also include models of ligament damage and bone fractures. BPC-157 improved the structural and biomechanical parameters of healing tissues, although the molecular mechanisms require further elucidation.
Gastroenterological tests
Due to its gastric origin, BPC-157 is intensively studied in the context of protecting the gastrointestinal mucosa. The peptide showed antiulcer activity in stress, ethanol, indomethacin and capsaicin-induced injury models. Clinical trials have been conducted in inflammatory bowel disease (IBD), although full results have not yet been published.
Cardiovascular research
BPC-157 is being studied for protecting the heart from damage, preventing arrhythmias, and modulating thrombosis. In models of large vessel occlusion, the peptide activated collateral circulation, preventing multi-organ failure.
Neurological examinations
In the context of the gut-brain axis, BPC-157 is being studied for anxiolytic, antidepressant, anticonvulsant effects and counteracting symptoms of catalepsy and schizophrenia-like models in rats. The peptide influenced the release of serotonin in specific areas of the brain, mainly in the nigrostriatal system.
Spinal cord injury research
Preliminary preclinical studies are examining the potential of BPC-157 to reduce inflammation and support nerve regeneration after spinal cord compression injuries.
Scientific context
BPC-157 fits into the concept of gastric cytoprotection proposed by André Robert, according to which peptides native to the gastrointestinal tract can exert a wide range of protective effects on various organs. This is consistent with the observation that compounds with potent antiulcer activity often also have beneficial effects in other tissues.
Compared to other regenerative peptides (such as TB-500/Thymosin β4 or collagen peptides), BPC-157 stands out:
- Stability in the gastric environment
- No media needed
- Efficacy in both local and systemic administration
- Action at very low doses (range ng/kg to µg/kg)
Regulatory status and safety
In 2023, the FDA classified BPC-157 as a Category 2 substance, meaning it cannot be formulated by commercial pharmaceutical companies due to insufficient human safety data.
In available preclinical studies, no significant toxic effects were noted over a wide range of doses. In the only published clinical pilot study (2025), intravenous administration of BPC-157 up to 20 mg was well tolerated, with no significant changes in vital signs, ECG or laboratory markers of heart, liver, kidney and thyroid function.
However, the long-term safety profile in humans remains unknown due to the limited number of clinical studies.
Bibliography - latest scientific research
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopedic Sports Medicine: A Systematic Review. Orthop J Sports Med. 2025;13(6). PMC
- Liao HJ, Chen HT, Chang CH. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMC
- Walczak M, et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals. 2025;18(2):185. MDPI
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain–Gut Axis and Gut–Brain Axis Function. Pharmaceuticals. 2023;16(5):676. PMC
- Kang EA, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022;17(3):482-487. PMC
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. PMC
- Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153-167. PMC
- Madzarac G, Vlainic J, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2017;15(6):857-865. PMC
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21(6):976-983. ScienceDirect
